Work

Pnflba-16 First Results of A-predict: a Phase Ii Study of Axitinib in Patients With Metastatic Renal Cell Cancer (rcc) Unsuitable for Nephrectomy

Year: 2017

Type: article

Abstract: adjusted (20) cut-points both result in NPV 90, with sensitivity of 94% and 92%, respectively.The number of avoided biopsies is greater (30%) with the adjusted cut-point of 20 vs. the original validated cutpoint (21%); while missing only 1>/¼ISUP 3 case.The original validated cut-point would have avoided biopsies in 30% of men with GS6 or benign disease while the adjusted cut-point would have avoided 43% of biopsies in this population.CONCLUSIONS: Interim results from a prospective adaptive trial of the EPI test demonstrate consistent performance as identified in the original validation study.The adjusted cut-point continues to provide added benefit without risk of missing significant disease.

Source: The Journal of Urology

DOI: 10.1016/j.juro.2017.03.042

Authors: Grant Stewart, James Morden, Ekaterini Boleti, Naveen Vasudev, Fiona Thistlethwaite, Agnieszka Michael, Lucy Kilburn, Rebecca Lewis, David Nicol, Linda Pyle, Claire Snowdon, Rachel Todd, Lucy Tregellas, Samra Turajlic, Charlie Swanton, Judith Bliss, James Larkin

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2604601553

FWCI:

Cites:

Cited by:

Related to: 10